Trial Profile

A Randomized Study to Investigate Injection-Site Pain Following Subcutaneous Injections of 2 Ixekizumab Test Formulations Compared to the Commercial Formulation Using a Pre-filled Syringe in Healthy Subjects

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 02 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ixekizumab (Primary)
Indications Ankylosing spondylitis; Bullous pemphigoid; Erythrodermic psoriasis; Juvenile rheumatoid arthritis; Pityriasis rubra pilaris; Plaque psoriasis; Psoriatic arthritis; Pustular psoriasis; Pyoderma gangrenosum; Spondylarthritis; Varicose ulcer
Focus Adverse reactions
Sponsors Eli Lilly and Company (India) Pvt. Ltd

28 Nov 2022 Status changed from completed to discontinued.
12 Apr 2022 Primary endpoint (Injection Pain Visual Analog Scale (VAS) Score) has been met according to the results published in the Advances in Therapy
12 Apr 2022 Results published in the Advances in Therapy

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com